The European Commission has approved expanded indication for linagliptin in a wider range of adult Type 2 Diabetes (T2D) patients
INGELHEIM, Germany - Friday, October 26th 2012 [ME NewsWire]
(BUSINESS WIRE)-- For Non-U.S. and Non-U.K. Media
Boehringer Ingelheim and Eli Lilly and Companytoday announced that the European Commission has approved an expanded therapeutic indication for the DPP-4 inhibitor Trajenta® (linagliptin) to include use in combination with insulin in adults with Type 2 Diabetes.
"We are delighted that approval has been granted for the use of linagliptin as an add-on to insulin in adults with Type 2 Diabetes,” said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim, "This expanded indication shows that linagliptin is an effective treatment for patients at various stages of Type 2 Diabetes.”
The approval means linagliptin is now indicated for use in combination with insulin with or without metformin,
...
Read more »